Is SIGA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Long-dated US government stockpile demand, with 2025 product revenue at About $88 million (per company results). The bear case rests on sIGA carries unusually concentrated risk for its size. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. SIGA carries unusually concentrated risk for its size. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Long-dated US government stockpile demand. SIGA's core revenue anchor is the BARDA 19C contract for the Strategic National Stockpile, structured as a multi-year agreement valued at up to roughly $629 million with a base period plus option years.

SIGA carries unusually concentrated risk for its size. Nearly all revenue comes from a single product, TPOXX, so any efficacy, safety or manufacturing setback would hit the whole business. Customer concentration is just as acute: the US government is by far the largest buyer, and contract timing, budget cycles and renewal of the BARDA agreement dominate results, making revenue lumpy from quarter to quarter, as the weak Q1 2026 showed. Regulatory risk is real on the mpox front, where some agencies have reviewed and questioned TPOXX's benefit for mpox treatment even though the core smallpox approval stands. International orders are episodic and hard to forecast, and a stockpile-driven model means demand can plateau once buyers are supplied. Special dividends are discretionary and not guaranteed to recur.

SIGA Technologies is a commercial-stage pharmaceutical company built around one product, TPOXX (tecovirimat), an antiviral approved by the FDA to treat smallpox in both oral and in

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Long-dated US government stockpile demand) stalling in the reported numbers rather than in the narrative, the risk above (sIGA carries unusually concentrated risk for its size) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals and risk tolerance, and this is not advice. Supporters point to consistent profitability, a cash-rich debt-free balance sheet and durable government demand for TPOXX. Skeptics point to reliance on a single product and a small set of government buyers, which makes revenue lumpy and hard to forecast. Review the latest filings and consider how much single-customer concentration you are comfortable with.

TPOXX (tecovirimat) is SIGA's antiviral drug, approved by the FDA to treat smallpox in both oral and intravenous forms. Because smallpox is eradicated in the wild, its practical role is as a biodefense countermeasure that governments stockpile against a potential release. It has also been studied for related orthopoxvirus infections such as mpox, though its benefit specifically for mpox treatment has faced regulatory questions.

There is no ordinary commercial market for a smallpox antiviral because the disease is eradicated. The buyers are governments building medical countermeasure stockpiles. SIGA's anchor customer is the US government through BARDA, which procures TPOXX for the Strategic National Stockpile, supplemented by episodic international orders. This makes contract awards, renewals and delivery timing the dominant drivers of SIGA's revenue.